Abstract 2312 Skin Barrier Lipid and Cytokine Abnormalities in Cancer Patients with Immune Related Cutaneous Adverse Events (ircAEs)
Objective: Immune-related cutaneous adverse events (ircAE) occur in ≥50% of patients treated with checkpoint inhibitors, but the underlying mechanisms for ircAEs are poorly understood. Experimental Design: Phenotyping/biomarker analyses were conducted in 200 patients on checkpoint inhibitors [139 with ircAEs and 61 without (control group)] to characterize their clinical presentation, lipid composition, and immunologic endotypes. Skin stratum corneum was collected using D-Squame skin tape strips (STS) from the area of ircAE manifestation (ircAE subjects) or the volar forearm area (controls).
Authors
- Irina Bronova (ORCID: https://orcid.org/0000-0003-0867-2496)
- Mario E. Lacouture (ORCID: https://orcid.org/0000-0002-4818-3710)
- Elena Goleva (ORCID: https://orcid.org/0000-0002-4685-9318)
- Ryan Weight (ORCID: https://orcid.org/0009-0006-0982-2096)
- Donald Y.M. Leung (ORCID: https://orcid.org/0000-0002-0177-3844)
- Taras Lyubchenko (ORCID: https://orcid.org/0000-0001-9466-5916)
- Evgeny Berdyshev (ORCID: https://orcid.org/0000-0002-1376-0098)
- Neil J. Shah (ORCID: https://orcid.org/0000-0001-5752-6212)
- J. Kern (ORCID: https://orcid.org/0000-0001-5019-4104)
Institutions
- National Jewish Health (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of Biological Chemistry
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.jbc.2025.108723
- Primary Topic
- Skin Diseases and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00